Objective: To compare the effectiveness and safety of vancomycin and teicoplanin in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infection in patient received liver-transpalnt operation in the intensive care unit (ICU). Methods: Twelve patients with MRSA infection were randomly divided into vancomycin group and teicoplanin group. Results: For the groups of vancomycin and teicoplanin, the total clinical effective rates were 71.4% and 60.0% (P<0.05); the bacteria clear rates were 88.2% and 86.7%; and the incidence of side effects were 28.5% and 60%, respectively. Conclusion: Vancomycin is more effective in the treatment of liver-transplanted patients with MRSA infection in ICU than teicoplanin, and can be used for these patients as preferred medication.%目的:比较万古霉素和替考拉宁治疗重症监护病房肝移植术后耐甲氧西林金黄色葡萄球(MRSA)感染的疗效和安全性.方法:将12例肝移植术后MRSA感染病人随机分为万古霉素治疗组和替考拉宁治疗组,比较两组病人应用抗生素后的治愈率和不良反应.结果:万古霉素与替考拉宁治疗MRSA的治愈率分别为71.4％和60.0％,细菌清除率分别为88.2％和86.7％,不良反应发生率为28.5％和60％,两组间MRSA治愈率有显著性差异(P＜0.05).结论:万古霉素对重症监护病房肝移植术后MRSA感染的早期治疗效果优于替考拉宁,可以作为此类病人的首选用药.
展开▼
